🇺🇸 FDA
Patent

US 11266746

Therapeutic antitumor combination of a TLR4 ligand with other treatments

granted A61KA61K31/4745A61K31/664

Quick answer

US patent 11266746 (Therapeutic antitumor combination of a TLR4 ligand with other treatments) held by The United Slates of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United Slates of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/4745, A61K31/664, A61K38/1709, A61K39/39558